Row
H
HIMSAI Stock Diagnostic Report
Hims CEO responds to FTC suit, sees GLP-1 prices falling to $40-$50: CNBC
The CEO of Hims responded to the FTC lawsuit and revealed expectations for a decline in GLP-1 drug prices.
View Source Article ↗
AI CATALYST SCORE50 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
HIMS Analysis History (Last 30 Days)